Literature DB >> 2954797

Lymphocyte subsets in primary sclerosing cholangitis.

K D Lindor, R H Wiesner, J A Katzmann, N F LaRusso, S J Beaver.   

Abstract

As an initial step in testing the hypothesis that immunoregulatory abnormalities are important in the pathogenesis of primary sclerosing cholangitis, we determined the number and percentage of lymphocyte subsets in the peripheral blood of 33 patients with primary sclerosing cholangitis. In these patients, when compared with normal and diseased controls, there was a significant reduction in the total number of circulating T cells because of a disproportionate decrease in Leu-2a (suppressor/cytotoxic) cells. This decrease resulted in a significantly increased ratio of Leu-3a to Leu-2a cells. Patients with cirrhosis had significantly higher Leu-3a/Leu-2a (helper/suppressor) ratios than did noncirrhotic patients; both disease groups, however, had ratios that were significantly higher than controls. The number and percentage of B cells were significantly increased. Alterations in the percentage of B cells correlated significantly with histologic stage and concentrations of gamma globulin, serum IgG, and bilirubin. We conclude that these abnormalities are suggestive of a defect in immunoregulation in primary sclerosing cholangitis, which is not secondary to advanced liver disease alone and appears to be independent of chronic ulcerative colitis or obstructive jaundice.

Entities:  

Mesh:

Year:  1987        PMID: 2954797     DOI: 10.1007/bf01296138

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Assessment of severity in colitis: a preliminary study.

Authors:  J E Lennard-Jones; J K Ritchie; W Hilder; C C Spicer
Journal:  Gut       Date:  1975-08       Impact factor: 23.059

2.  Elevated circulating immune complexes in primary sclerosing cholangitis.

Authors:  H C Bodenheimer; N F LaRusso; W R Thayer; C Charland; P J Staples; J Ludwig
Journal:  Hepatology       Date:  1983 Mar-Apr       Impact factor: 17.425

3.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.

Authors:  J Ludwig; S S Barham; N F LaRusso; L R Elveback; R H Wiesner; J T McCall
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

4.  Loss of suppressor T-cells in active inflammatory bowel disease.

Authors:  N J Godin; D B Sachar; R Winchester; C Simon; H D Janowitz
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

5.  HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease.

Authors:  E Schrumpf; O Fausa; O Førre; J H Dobloug; S Ritland; E Thorsby
Journal:  Scand J Gastroenterol       Date:  1982-03       Impact factor: 2.423

6.  Current concepts. Primary sclerosing cholangitis.

Authors:  N F LaRusso; R H Wiesner; J Ludwig; R L MacCarty
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

7.  Association of primary sclerosing cholangitis with HLA-B8.

Authors:  R W Chapman; Z Varghese; R Gaul; G Patel; N Kokinon; S Sherlock
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

8.  Active T rosettes, human autologous T rosettes, OKT8 and OKT4 cells, con A-induced suppressive activity, and autoantibodies: clinical correlations.

Authors:  L Schandené; F Vanden Steen; F Romasco; J Wybran
Journal:  Clin Immunol Immunopathol       Date:  1983-08

9.  Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis.

Authors:  R H Wiesner; N F LaRusso; J Ludwig; E R Dickson
Journal:  Gastroenterology       Date:  1985-01       Impact factor: 22.682

10.  The in vivo metabolism of C3 in hepatobiliary disease associated with ulcerative colitis.

Authors:  L Brinch; P Teisberg; E Schrumpf; I Akesson
Journal:  Scand J Gastroenterol       Date:  1982-06       Impact factor: 2.423

View more
  16 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 3.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

4.  Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study.

Authors:  A E Kilby; E L Krawitt; R J Albertini; B F Chastenay; A John
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

Review 5.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 6.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

7.  Tissue distribution of autoantigen specific for primary sclerosing cholangitis.

Authors:  S K Lo; R W Chapman; K A Fleming
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

Review 8.  The immunology of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Springer Semin Immunopathol       Date:  1990

9.  Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis.

Authors:  S Bloom; A Heryet; K Fleming; R W Chapman
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

10.  Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases.

Authors:  T H J Florin; N Pandeya; G L Radford-Smith
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.